Abstract
The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosinekinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.
Original language | English |
---|---|
Pages (from-to) | 10-18 |
Number of pages | 9 |
Journal | Journal of Cellular Physiology |
Volume | 205 |
Issue number | 1 |
DOIs | |
Publication status | Published - Oct 2005 |
ASJC Scopus subject areas
- Clinical Biochemistry
- Cell Biology
- Physiology